Article

Alcon to proceed with corrective action plan for vitreoretinal system

Alcon Laboratories announced that it received clearance from the FDA to complete its voluntary medical device corrective action plan on its proprietary vitreoretinal system (Constellation Vision System) in the United States.

Huenenberg, Switzerland-Alcon Laboratories announced that it received clearance from the FDA to complete its voluntary medical device corrective action plan on its proprietary vitreoretinal system (Constellation Vision System) in the United States.

Alcon submitted a 510(k) for the voluntary corrective action plan to the FDA in May. The plan included specific hardware and software modifications to address identified reported events.

“We are pleased to have received clearance from the FDA and we will now proceed with our plan to upgrade [the system],” said Stuart Raetzman, vice president, global marketing and area president for the United States. “These modifications have been successful outside the United States and we are confident they will address the identified performance issues and allow our customers to use the . . . vision system without any restrictions.”

Alcon established a loaner program to provide support to customers affected by its voluntary corrective action plan. This program allowed physicians to continue providing high-quality vitreoretinal surgery to their patients while the company was waiting for the FDA clearance of the modifications. The program provided surgical systems (ACCURUS), lasers (PUREPOINT), and other needed surgical accessories.

Alcon said in a prepared statement that it will work as quickly as possible to implement the modifications to existing customer systems and these modifications will be immediately included with all new system installations. Alcon’s technical customer service team will contact customers to schedule the modifications for the vitreoretinal system.

For assistance and questions, customers may contact their Alcon surgical sales representative or technical consumer affairs at 800/561-6466, option 8.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.